ARGX
Price
$602.17
Change
+$7.52 (+1.26%)
Updated
Apr 24, 02:16 PM (EDT)
Capitalization
36.47B
14 days until earnings call
IONS
Price
$29.16
Change
+$0.06 (+0.21%)
Updated
Apr 24, 02:33 PM (EDT)
Capitalization
4.63B
6 days until earnings call
Ad is loading...

ARGX vs IONS

Header iconARGX vs IONS Comparison
Open Charts ARGX vs IONSBanner chart's image
argenx SE
Price$602.17
Change+$7.52 (+1.26%)
Volume$291
Capitalization36.47B
Ionis Pharmaceuticals
Price$29.16
Change+$0.06 (+0.21%)
Volume$28.93K
Capitalization4.63B
ARGX vs IONS Comparison Chart
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. IONS commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Buy and IONS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ARGX: $594.65 vs. IONS: $29.10)
Brand notoriety: ARGX and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 64% vs. IONS: 60%
Market capitalization -- ARGX: $36.47B vs. IONS: $4.63B
ARGX [@Biotechnology] is valued at $36.47B. IONS’s [@Biotechnology] market capitalization is $4.63B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGX is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 5 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 3 bearish.
  • IONS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ARGX is a better buy in the short-term than IONS.

Price Growth

ARGX (@Biotechnology) experienced а +1.20% price change this week, while IONS (@Biotechnology) price change was +2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

ARGX is expected to report earnings on Jul 31, 2025.

IONS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($36.5B) has a higher market cap than IONS($4.63B). ARGX YTD gains are higher at: -3.309 vs. IONS (-16.762). ARGX has higher annual earnings (EBITDA): -60.47M vs. IONS (-353.72M). ARGX has more cash in the bank: 3.1B vs. IONS (2.3B). ARGX has less debt than IONS: ARGX (34M) vs IONS (1.42B). ARGX has higher revenues than IONS: ARGX (1.86B) vs IONS (705M).
ARGXIONSARGX / IONS
Capitalization36.5B4.63B789%
EBITDA-60.47M-353.72M17%
Gain YTD-3.309-16.76220%
P/E Ratio46.53N/A-
Revenue1.86B705M264%
Total Cash3.1B2.3B135%
Total Debt34M1.42B2%
FUNDAMENTALS RATINGS
ARGX vs IONS: Fundamental Ratings
ARGX
IONS
OUTLOOK RATING
1..100
1310
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
4579
P/E GROWTH RATING
1..100
4957
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARGX's Valuation (78) in the Pharmaceuticals Other industry is in the same range as IONS (96) in the Biotechnology industry. This means that ARGX’s stock grew similarly to IONS’s over the last 12 months.

ARGX's Profit vs Risk Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that ARGX’s stock grew significantly faster than IONS’s over the last 12 months.

ARGX's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as IONS (95) in the Biotechnology industry. This means that ARGX’s stock grew similarly to IONS’s over the last 12 months.

ARGX's Price Growth Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for IONS (79) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than IONS’s over the last 12 months.

ARGX's P/E Growth Rating (49) in the Pharmaceuticals Other industry is in the same range as IONS (57) in the Biotechnology industry. This means that ARGX’s stock grew similarly to IONS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXIONS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 2 days ago
61%
Declines
ODDS (%)
Bearish Trend 9 days ago
61%
Bearish Trend 9 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FMED23.020.43
+1.91%
Fidelity Disruptive Medicine ETF
MLPA49.950.26
+0.52%
Global X MLP ETF
VTN10.000.05
+0.50%
Invesco Trust for Investment Grade New York Municipals
FLDZ26.43N/A
N/A
RiverNorth Patriot ETF
RSPG70.61-0.03
-0.04%
Invesco S&P 500® Equal Weight Energy ETF

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
-0.87%
ARGNF - ARGX
55%
Loosely correlated
N/A
BBIO - ARGX
46%
Loosely correlated
+3.07%
IONS - ARGX
45%
Loosely correlated
+0.24%
ROIV - ARGX
41%
Loosely correlated
+2.98%
ALNY - ARGX
41%
Loosely correlated
+2.20%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+0.24%
ALNY - IONS
52%
Loosely correlated
+2.20%
IDYA - IONS
48%
Loosely correlated
+0.91%
RCKT - IONS
47%
Loosely correlated
+2.44%
RARE - IONS
47%
Loosely correlated
+3.90%
ROIV - IONS
47%
Loosely correlated
+2.98%
More